An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase

Antimicrob Agents Chemother. 2016 May 23;60(6):3270-5. doi: 10.1128/AAC.03118-15. Print 2016 Jun.

Abstract

We describe a 16-year-old neutropenic patient from the Middle East with bloodstream infection caused by two carbapenemase-producing Escherichia coli isolates that we characterized by whole-genome sequencing. While one displayed meropenem resistance and was blaNDM positive, the other demonstrated meropenem susceptibility yet harbored blaOXA181 (which encodes a blaOXA48-like enzyme). This report highlights the challenge of laboratory detection of blaOXA48-like enzymes and the clinical implications of genotypic resistance detection in carbapenemase-producing Enterobacteriaceae.

MeSH terms

  • Adolescent
  • Amikacin / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Aztreonam / pharmacology
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism*
  • Ciprofloxacin / pharmacology
  • Ertapenem
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology*
  • Escherichia coli / genetics
  • Female
  • Gentamicins / pharmacology
  • Humans
  • Immunocompromised Host
  • Meropenem
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / pharmacology
  • Piperacillin / pharmacology
  • Piperacillin, Tazobactam Drug Combination
  • Tazobactam
  • Thienamycins / pharmacology
  • Tobramycin / pharmacology
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*
  • beta-Lactams / pharmacology

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Gentamicins
  • Thienamycins
  • beta-Lactams
  • Piperacillin, Tazobactam Drug Combination
  • Ciprofloxacin
  • Amikacin
  • Penicillanic Acid
  • beta-Lactamases
  • carbapenemase
  • Meropenem
  • Aztreonam
  • Ertapenem
  • Tazobactam
  • Tobramycin
  • Piperacillin

Grants and funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.